Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT - CD
NCT03219359Phase 2Recruiting
- Sponsor
- Aaron Etra
- Start
- Feb 2018
- Primary completion
- Oct 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in Crohn's disease, sponsored by Aaron Etra. Started Feb 2018; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03219359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219359.